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Abstract
Background. The ‘jumping to conclusions’ (JTC) bias is associated with both psychosis and
general cognition but their relationship is unclear. In this study, we set out to clarify the rela-
tionship between the JTC bias, IQ, psychosis and polygenic liability to schizophrenia and IQ.
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Methods. A total of 817 first episode psychosis patients and 1294 population-based controls
completed assessments of general intelligence (IQ), and JTC, and provided blood or saliva sam-
ples from which we extracted DNA and computed polygenic risk scores for IQ and schizophrenia.
Results. The estimated proportion of the total effect of case/control differences on JTC
mediated by IQ was 79%. Schizophrenia polygenic risk score was non-significantly associated
with a higher number of beads drawn (B = 0.47, 95% CI −0.21 to 1.16, p = 0.17); whereas IQ
PRS (B = 0.51, 95% CI 0.25–0.76, p < 0.001) significantly predicted the number of beads
drawn, and was thus associated with reduced JTC bias. The JTC was more strongly associated
with the higher level of psychotic-like experiences (PLEs) in controls, including after controlling
for IQ (B =−1.7, 95% CI −2.8 to −0.5, p = 0.006), but did not relate to delusions in patients.
Conclusions. Our findings suggest that the JTC reasoning bias in psychosis might not be a spe-
cific cognitive deficit but rather a manifestation or consequence, of general cognitive impairment.
Whereas, in the general population, the JTC bias is related to PLEs, independent of IQ. The work
has the potential to inform interventions targeting cognitive biases in early psychosis.
Introduction
Jumping to conclusions (JTC) is a well-established reasoning and
data gathering bias found in patients with psychosis (Dudley,
Taylor, Wickham, & Hutton, 2016; Garety & Freeman, 2013;
So, Siu, Wong, Chan, & Garety, 2016). It is usually measured
by a reasoning task based on a Bayesian model of probabilistic
inference known as the ‘beads task’ (Dudley, John, Young, &
Over, 1997; Huq, Garety, & Hemsley, 1988).
Early work investigating reasoning bias through beads in jars
paradigm focused on the association with delusions, finding
that patients with delusions tend to require fewer beads to reach
a decision than would be expected following Bayesian norms
(Huq et al., 1988). In this respect, it has been suggested that
data-gathering bias represents a key cognitive component in
delusion formation and maintenance (Garety & Freeman,
1999). Although most of the studies endorsing this association
used a cross-sectional design, comparing those with and without
delusions in samples of patients with schizophrenia or other
psychoses (Freeman et al., 2014; Garety et al., 2013),
meta-analyses mostly found a weak association with delusions,
yet a clear association with psychosis (Dudley et al., 2016; Fine,
Gardner, Craigie, & Gold, 2007; Ross, McKay, Coltheart, &
Langdon, 2015; So et al., 2016). Moreover, JTC was found not
only in non-delusional and remitted patients with schizophrenia,
but also in individuals at clinical high risk and first-degree rela-
tives (Broome et al., 2007; Menon, Pomarol-Clotet, McKenna,
& McCarthy, 2006; Moritz & Woodward, 2005; Peters &
Garety, 2006; Van Dael et al., 2005).
Overall, these findings suggest that JTC could play a role in the
liability for psychotic disorders, perhaps serving as an endophe-
notype associated with the genetic risk. As a highly heritable
and polygenic disorder, many common genetic variants contrib-
ute to the risk of schizophrenia, which can be summarised into an
individual polygenic risk score (PRS) (Purcell et al., 2009;
Schizophrenia Working Group of the Psychiatric Genomics,
2014). Genome-wide association studies (GWAS) have found a
significant genetic overlap between cognition and schizophrenia
(Mistry, Harrison, Smith, Escott-Price, & Zammit, 2018; Ohi
et al., 2018; Shafee et al., 2018), and a recent study by
Toulopoulou (Toulopoulou et al., 2018) showed that the variance
in schizophrenia liability explained by PRS was partially mediated
through cognitive deficit. Despite a large body of literature on the
JTC bias describing it as a potential intermediate phenotype, to
date there has been no investigation into the possible genetic
overlap with psychosis through the PRS strategy. Nonetheless,
there is a considerable amount of literature suggesting a link
between JTC and cognitive functions. Cross-sectional studies on
both recent onset psychosis and schizophrenia suggest that
patients who present with neuropsychological deficits, especially
involving executive functions, display more tendency to jump to
conclusions (Garety et al., 2013; González et al., 2018). Those
findings appear to be corroborated by the study of Lunt (Lunt
et al., 2012) where JTC bias was found to be more prominent
in individuals with prefrontal lesions, especially on the left side
of the cortex, compared with controls. Woodward (Woodward,
Mizrahi, Menon, & Christensen, 2009), using a principal compo-
nent analysis (PCA) in a sample of inpatients with schizophrenia
found that neuropsychological functions and JTC loaded on the
same factor. Similar findings were obtained in a confirmatory fac-
tor analysis on psychotic patients with delusions and controls
(Bentall et al., 2009). Interestingly in the latter, when general cog-
nitive functioning was included in the model, the association
between paranoia and JTC no longer held. In their study compar-
ing patients with delusions, remitted patients with schizophrenia,
and controls, Lincoln (Lincoln, Ziegler, Mehl, & Rief, 2010)
found that, after taking intelligence into account, not only the
association between JTC and delusions disappeared, but the
group effect on the JTC bias was not detected any longer.
Likewise, general intelligence affected statistically the relation
between JTC and psychosis liability in the van Dael study (Van
Dael et al., 2005). Lower IQ was also found associated with JTC
in first episode psychosis (FEP) (Catalan et al., 2015; Falcone
et al., 2015). Nonetheless, other studies on early psychosis did not
detect any association with cognition, possibly due to the small
sample size (Langdon, Still, Connors, Ward, & Catts, 2014;
Ormrod et al., 2012).
Thus, although many studies highlighted that JTC is strongly
associated with delusions, and more broadly with psychosis, this
association seems to be affected by the general cognitive function.
To address this question robustly requires a large sample size,
whereas most previous studies of JTC in psychiatry have had
moderate sample sizes of between 20 and 100 patients.
Therefore, we used data from the large multi-country EUropean
Network of national schizophrenia networks studying the
Gene-Environment Interactions (EUGEI) case-control study of
FEP to investigate whether IQ plays a role as mediator in the path-
way between the bias and the disorder. We also aimed to investi-
gate whether JTC is associated with the liability for psychotic
disorders and/or liability to general intellectual function.
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Therefore, in this study we aim to test the following
predictions:
(1) The JTC bias will be best predicted by clinical status through
IQ mediation;
(2) The JTC bias will be predicted by the polygenic risk score for
schizophrenia (SZ PRS) and by the polygenic risk score for IQ
(IQ PRS).
(3) The JTC bias will be predicted by delusions in patients and
psychotic-like experiences (PLEs) in controls.
Methods
Participants
Participants were recruited and assessed as part of the incidence
and first episode case-control study, conducted as part of the
EU-GEI programme (Di Forti et al., 2019; Gayer-Anderson,
2019; Jongsma et al., 2018). The study was designed to investigate
risk factors for psychotic disorders between 1 May 2010 and 1
April 2015 in 17 sites ranging from rural to urban areas in
England, France, the Netherlands, Italy, Spain and Brazil.
All participants provided informed, written consent following
full explanation of the study. Ethical approval was provided by
relevant research ethics committees in each of the study sites.
Patients with a FEP were recruited through regular checks across
the 17 defined catchment areas Mental Health services to identify
all individuals aged 18–64 years who presented with a FEP during
the study period. Patients were included if they met the following
criteria during the recruitment period: (a) aged between 18 and
64 years; (b) presentation with a clinical diagnosis for an
untreated FEP, even if longstanding [International Statistical
Classification of Diseases and Related Health Problems, Tenth
Revision (ICD-10) codes F20–F33] and (c) resident within the
catchment area at FEP. Exclusion criteria are: (a) previous
contact with psychiatric services for psychosis; (b) psychotic
symptoms with any evidence of organic causation and (c) transi-
ent psychotic symptoms resulting from acute intoxication
(ICD-10: F1x.5).
Inclusion criteria for controls are: (a) aged between 18 and 64
years; (b) resident within a clearly defined catchment area at the
time of consent into the study; (c) sufficient command of the pri-
mary language at each site to complete assessments and (d) no cur-
rent or past psychotic disorder. To select a population-based
sample of controls broadly representative of local populations in
relation to age, gender and ethnicity, a mixture of random and
quota sampling was adopted. Quotas for control recruitment
were based on the most accurate local demographic data available,
and then filled using a variety of recruitment methods, including
through: (1) random sampling from lists of all postal addresses
(e.g. in London); (2) stratified random sampling via general prac-
tice (GP) lists (e.g. in London and Cambridge) from randomly
selected surgeries and (3) ad hoc approaches (e.g. internet and
newspaper adverts, leaflets at local stations, shops and job centres).
Measures
Detailed information on age, sex, self-reported ethnicity, level of
education and social networks was collected using the Medical
Research Council (MRC) Sociodemographic Schedule (Mallett,
1997).
The short form of the WAIS III was administered as an indi-
cator of general cognitive ability (IQ) and includes the following
subtests: information (verbal comprehension), block design (rea-
soning and problem solving), arithmetic (working memory) and
digit symbol-coding (processing speed). This short form has
been shown to give reliable and valid estimates of Full-Scale IQ
in schizophrenia (Velthorst et al., 2013).
Following instructions and practice, the JTC bias was assessed
using a single trial of the computerised 60:40 version of the beads
task. In this task, there are two jars containing coloured beads
with a complementary ratio (60 : 40). One jar is chosen, and
beads are drawn one at time and shown to the participants follow-
ing the pattern: BRRBBRBBBRBBBBRRBRRB, where B indicates
a blue bead and R indicates red. After each draw they are required
to either decide from which jar the beads have come or defer the
decision (up to a maximum of 20 beads). This single-trial experi-
ment was terminated when the participant made the decision of
which jar the beads were being drawn from. The key outcome
variable employed as an index of the JTC bias was the number
of ‘Draws-To-Decision’ (DTD); the lower the DTD, the greater
the JTC bias. The binary JTC variable based on the choice of 2
or less beads before answering the task was also employed.
Psychopathology was assessed using the OPerational CRITera
system (OPCRIT) (McGuffin, Farmer, & Harvey, 1991). Item
response modelling was previously used to develop a bi-factor
model composed of general and specific dimensions of psychotic
symptoms, which include the positive symptom dimension
(delusion and hallucination items) (Quattrone et al., 2018). For
the purposes of the present work, we adapted the previous
method to estimate an alternative bi-factor model comprising
two discrete hallucination and delusion symptom dimensions,
instead of a single positive symptom dimension. We assessed
PLEs in controls through the Community Assessment of
Psychic Experience (CAPE) (Stefanis et al., 2002) positive dimen-
sion score (online Supplementary Table S1). The CAPE is a self-
report questionnaire with good reliability for all the languages
spoken in the EUGEI catchment areas (http://www.cape42.home-
stead.com/).
Polygenic risk scores
The case-control genotyped WP2 EUGEI sample (N = 2169;
cases’ samples N = 920, controls’ samples N = 1248) included
DNA extracted from blood (N = 1857) or saliva (N = 312). The
samples were genotyped at the MRC Centre for Neuropsychiatric
Genetics and Genomics in Cardiff (UK) using a custom Illumina
HumanCoreExome-24 BeadChip genotyping array covering
570 038 genetic variants. After genotype Quality Control, we
excluded SNPs with minor allele frequency <0.5%, Hardy
Weinberg Equilibrium p < 10–6, missingness >2%. After sample
Quality Control, we excluded samples with >2% missingness, het-
erozygosity Fhet >0.14 or <−0.11, who presented genotype–pheno-
type sex mismatch or who clustered with homogenous black
ancestry in PCA analysis (N = 170). The final sample was com-
posed of 1720 individuals (1112 of European ethnicity, 608 of
any other ethnicities but not black African), of which 1041 controls
and 679 patients. Imputation was performed through the Michigan
Imputation Server, using the Haplotype Reference Consortium ref-
erence panel with the Eagle software for estimating haplotype
phase, and Minimac3 for genotype imputation (Das et al., 2016;
Loh et al., 2016; McCarthy et al., 2016). The imputed variants
with r2 < 0.6, MAF <0.1% or missingness >1% were excluded.
Psychological Medicine 3
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The PRS for schizophrenia and IQ was built using, as training
data sets, the results from the last available mega-analysis from the
Psychiatric Genomics Consortium (PGC) (Schizophrenia Working
Group of the Psychiatric Genomics, 2014) and Savage et al. (2018)
respectively. In PRSice, individuals’ number of risk alleles in the
target sample was weighted by the log odds ratio from the discovery
samples and summed into the PRSs at a 0.05 SNPs Pt-thresholds
(apriori selected). We excluded people of homogeneous African
ancestry since in this population the SZ PRS from the PGC2 we
calculated, as reported by other studies (Vassos et al., 2017), failed
to explain a significant proportion of the variance (R2 = 1.1%,
p = 0.004).
Design and procedure
The EU-GEI study WP2 employed a case-control design collect-
ing data with an extensive battery of demographic, clinical, social
and biological measures (Core assessment); psychological mea-
sures, and cognitive tasks. All EU-GEI WP2 participants with
JTC and IQ data were included in the current study. All the
researchers involved in administrating the assessments undertook
a training organised by a technical working committee of the overall
EU-GEI study (Work Package 11) at the beginning and throughout
the study. Inter-rater reliability was assessed annually to warrant the
comparability of procedures and methods across sites.
Statistical analysis
Analyses were conducted in STATA 15 (StataCorp., 2017).
Preliminary descriptive analyses were performed using χ2 and t
tests to examine the differences in age, sex, ethnicity, level of edu-
cation, IQ and DTD between cases and controls. To test possible
statistical mediation by IQ as intervening variable between case/
control status and DTD, we applied Baron and Kenny’s procedure
(1986). According to the authors, a mediation can be established
when (1) variations in the independent variable (IV) significantly
account for variations in the dependent variable (DV); (2) varia-
tions in the IV significantly account for variations in the mediator
variable (Rimvall et al.); (3) variations in the MV significantly
account for variations in the DV and (4) a previous significant
effect of IV on DV is markedly decreased after controlling for
MV. Perfect mediation occurs when the independent variable has
no effect after controlling for the mediator (Baron & Kenny, 1986).
The STATA 15 sgmediation command was used to perform
three OLS regressions according to Baron and Kenny’s steps as
follows: (1) DTD (DV) regressed on case/control status (IV) –
Path c, (2) IQ (MV) regressed on case/control status (IV) –
Path a, (3) DTD (DV) regressed on IQ (MV) and case/control
status (IV) – Path b and c’ (Fig. 1). All the steps included as cov-
ariates age, sex, ethnicity and country. Furthermore, to generate
confidence intervals for the indirect effect, 5000 bootstrap replica-
tions were performed (Preacher & Hayes, 2008) and a non-
parametric confidence interval based on the empirical sampling
distributions was constructed.
To investigate whether JTC was associated with the liability for
psychotic disorders and general intelligence, we firstly tested the
accuracy of the PRSs to predict their primary phenotypes (case/con-
trol status and IQ) in our sample through logistic and linear regression
models respectively. Then, we built and compared linear regression
models regressing DTD on (1) case/control status, controlling for
age, sex and 20 principal components for population stratification;
(2) SZ PRS and (3) IQ PRS, adjusting for case/control status, age,
sex, IQ and 20 principal components for population stratification.
Linear regression models were built to test the effect of the
delusion symptom dimension on DTD, adding in the second
step as covariates age, sex, ethnicity, IQ and country, in patients.
We ran the same models in controls using the CAPE positive
score as a predictor.
We repeated all the analyses using as a secondary outcome the
binary variable JTC/no JTC (see online supplementary material).
Fig. 1. Mediation model between caseness (IV), IQ
(MV) and DTD (DV).
Note: DTD, draws-to-decision; IQ, intelligent quotient.
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Results
Sample characteristics
Cases and controls recruited as part of the EU-GEI study were
included in the current study if data on both Beads task and
WAIS were available. This led to a sample of FEP cases = 817
and controls N = 1294 for the mediation analysis (Fig. 2).
Cases were more often younger (cases mean age = 30.6 ± 10.4
v. controls mean age = 36.2 ± 13.1; t = 10.3, p < 0.001), men
[cases 61.2% (500) v. controls 47.5 (615); χ2(1) = 37.6, p < 0.001]
and from minority ethnic backgrounds (χ2(6) = 48.3, p < 0.001)
compared to controls (Table 1). The aforementioned differences
are those expected when comparing psychotic patients with the
general population.
The analysis of PRSs was performed in a subsample of 519
FEP and 881 population controls with available GWAS data.
Jumping to conclusions, psychosis and IQ
The results of the mediation model are displayed in Fig. 3. There
was evidence of a negative association between caseness and DTD
in path c [B = −1.4 (0.2); 95% CI −1.8 to −0.9; p < 0.001; adjusted
R2 = 8%]; as well as with IQ in Path a [B =−16. 7 (0.8); 95% CI
−18.24 to −15.10; p < 0.001]. Path b showed that higher IQ scores
Fig. 2. FEP recruitment flowchart.
Table 1. Demographic and cognitive characteristics of the sample included in the analysis
Controls N = 1294 FEP N = 817 df Test statistics p value
Age (mean; S.D.) 36.2 (13.1) 30.6 (10.4) 2109 T = 10.3 p < 0.001
Sex (male %; N ) 47.5 (615) 61.2 (500) 1 χ2 = 37.6 p < 0.001
Ethnicity (%; N )
White 77.9 (1009) 65.1 (531) 6 χ2 = 48.3 p < 0.001
Black 8.4 (109) 14.9 (122)
Mixed 7.9 (102) 10.5 (86)
Asian 2.3 (30) 2.8 (23)
North African 1.6 (21) 4.0 (33)
Other 1. 8 (23) 2.6 (21)
Education (%; N )
Left school with no qualifications 4.5 (58) 15.2 (124) 3 χ2 = 202.5 p < 0.001
School with qualifications 13.3 (172) 26.6 (217)
Tertiary & Vocational 42.9 (555) 41.9 (343)
Undergraduate & Postgraduate 38.9 (503) 15.9 (130)
Missing 0.5 (6) 0.4 (3)
IQ (mean; S.D.) 102.6 (17.8) 85.2 (18.1) 2109 T = 21.8 p < 0.001
DTD (mean; S.D.) 4.9 (4.7) 3.7 (4.3) 2109 T = 5.5 p < 0.001
Note: DTD, draws-to-decision; IQ, intelligent quotient.
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were significantly related to more DTD [B = 0.06 (0.01); 95% CI
0.05–0.07; p < 0.001]. The direct effect of case status on DTD dis-
played in path c’ markedly dropped from −1.4 to −0.3 and was no
longer statistically significant [B =−0.3 (0.2); 95% CI −0.7 to 0.1;
p = 0.19]. The estimated proportion of the total effect of case sta-
tus on DTD mediated by IQ was 79% and the variance explained
by the model rose to 14%. After performing 5000 bootstrap repli-
cations, the estimated indirect effect remained statistically signifi-
cant [B =−0.2 (0.02); 95% CI −0.3 to −0.2].
Jumping to conclusions, SZ PRS and IQ PRS
Sz PRS was a predictor for case status (OR 5.3, 95% CI 3.7–7.5,
p < 0.001), explaining 7% of the variance, as well as IQ PRS for
IQ (B = 3.9, 95% CI 2.9–4.9, p < 0.001), accounting for 14% of
the variance. As is shown in Table 2, SZ PRS was not significantly
associated with JTC, but in fact was non-significantly association
with increased numbers of beads drawn (B = 0.5, 95% CI −0.2 to
1.2, p = 0.17); whereas IQ PRS was positively associated with the
number of beads drawn (B = 0.5, 95% CI 0.3–0.8, p < 0.001).
When adding the IQ PRS to case-control status as a predictor
of DTD, the variance explained rose to 10%, of which 1% was
due to the PRS term. This relationship held even after adjusting
for IQ (B = 0.3, 95% CI 0.1–0.6, p = 0.017).
Jumping to conclusions, positive symptoms and psychotic-like
experiences
The delusion symptom dimension was positively associated with
DTD (B = 0.4, 95% CI 0.1–0.8, p = 0.013), although the associ-
ation became less accurate when adjusting for age, sex, ethnicity,
IQ and country, with the 95% confidence interval including zero
effect (B = 0.1, 95% CI −0.2 to 0.4, p = 0.531). The hallucination
dimension was not a robust predictor of DTD, whether or not
covariates were modelled (unadjusted B =−0.3, 95% CI −0.7 to
0.1, p = 0.089). Whereas the CAPE positive symptoms score was
negatively associated with the number of beads requested by con-
trols (B =−2.5, 95% CI −3.8 to −1.3, p < 0.001), which remained
significant even after controlling for age, sex, ethnicity, IQ and
country (B =−1.7, 95% CI −2.8 to −0.5, p = 0.006).
Discussion
The present study was conducted to investigate the relation
between the JTC bias and general cognitive ability in the first epi-
sode psychotic patients. We used the largest to date incidence
sample of FEP patients and population-based controls with avail-
able data on the JTC bias to address the question: is the link
between the bias and the disorder better explained by the medi-
ation of IQ? Moreover, this is the first study to test the association
between JTC and genetic susceptibility to schizophrenia.
We found that IQ is accountable for about 80% of the effect of
caseness on JTC. The data in fact indicated that case control dif-
ferences in JTC were not only partially mediated by IQ but were
fully mediated by IQ. In other words, the JTC bias in FEP might
not be an independent deficit but part of general cognitive
impairment. We obtained similar results also using the binary
outcome JTC yes/no (see online supplementary material).
Previous studies focusing on different explanations between the
JTC bias and psychotic disorder suggested that deluded patients
tend to request less information because sampling itself might
be experienced as more costly than it would be by healthy people
(Ermakova et al., 2018; Moutoussis, Bentall, El-Deredy, & Dayan,
2011). Although patients at onset seem to adjust their strategy
according to the cost of sampling where clearly stated and show
more bias to sample less information in the classic task, general
cognitive ability still plays an important role in their decision-
making behaviour (Ermakova et al., 2018; Moutoussis et al.,
2011). Indeed, the inclusion of general cognitive ability in the
relation between JTC and clinical status was reported to
Fig. 3. Mediation results.
Note: DTD, draws-to decision; IQ, intelligent quotient.
**p < 0.001.
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substantially decrease or nullify a prior significant association
(Falcone et al., 2015; Lincoln et al., 2010; Van Dael et al., 2005).
Our results are consistent with these studies and provide the
first evidence that the genetic variants associated with IQ are
negatively correlated with JTC, therefore endorsing the hypothesis
that cognition as endophenotype mediates the relation between
the bias and the liability for psychotic disorders.
In our study SZ PRS was not significantly associated with JTC.
However, as the PRS technique is based on contribution of com-
mon SNPs variation to genetic risk, its detection is strictly
dependent on statistical power (Smoller et al., 2019; Wray et al.,
2014). Although GWAS studies on schizophrenia have already
identified a substantial number of genetic variants by increasing
sample size (Schizophrenia Working Group of the Psychiatric
Genomics, 2014), SZ PRS still accounts for 7% of the variance
in schizophrenia liability, as we also found in our sample.
Whereas, IQ PRS is based on a far larger GWAS (Savage et al.,
2018), explaining as twice the variance as SZ PRS in our study.
We note that the effect sizes (quantified by estimated regression
parameters) between the schizophrenia PRS and DTD was similar
in size to, but, contrary to expectation, in the same direction as, the
effect size between the IQ PRS and DTD (but note the former
association was non-significant). Another possible explanation
lies in the fact that JTC seems to be more associated with the con-
tinuous distribution of delusions rather than with schizophrenia
per se (Broome et al., 2007; Menon et al., 2006; Moritz &
Woodward, 2005; Peters & Garety, 2006; Van Dael et al., 2005).
In fact, in a large case-control study on FEP patients carried
out by Falcone et al. (2015), adjusting for IQ and working mem-
ory abolished the relation between JTC and clinical status, but the
association between JTC and delusion severity remained. Perhaps
building a PRS based on the positive symptom dimension or delu-
sions would be more associated with the bias. However, in line
with a recent finding that patients with higher delusion severity
may have a tendency to increased information seeking (Baker,
Horga, Konova, & Daw, 2019), we found delusions were asso-
ciated with higher number of beads drawn, although with a
small effect size and attenuation after adjustment. Whereas, the
direction of the effect of PLE on the number of beads requested
by controls was expected (Freeman, Pugh, & Garety, 2008;
Reininghaus et al., 2018; Ross et al., 2015), and more interestingly
independent from IQ. Perhaps in the absence of general cognitive
impairment, the tendency to JTC contributes to PLE independent
of general intellectual function, whereas in the context of disorder
with general cognitive impairment, the JTC bias may not specif-
ically relate to the pathogenesis of psychosis. Future research is
warranted to further address this relation.
Strengths and limitations
Our study has several advantages. These include the large sample
size, the study of patients at the onset of illness and population
controls. There are limitations to our study. Although the sample
size is several times larger than any individual previous study, it is
still modest by genomic standards. We only included a single trial
of the task, as previous research has indicated that the measure of
DTD is very reliable over trials (Ermakova et al., 2018; Ermakova,
Ramachandra, Corlett, Fletcher, & Murray, 2014), to facilitate data
collection in this large multi-centre study. It can be argued that
only performing one trial using the higher cognitive demanding
60:40 version could capture more miscomprehension of the task
rather than truly the bias, resulting in overestimating its presence
(Balzan, Delfabbro, & Galletly, 2012a; Balzan, Delfabbro, Galletly,
& Woodward, 2012b). However, the beads task employed in the
study included a practice exercise before the trial. Moreover, the
difference between means of beads requested by cases and con-
trols in our study was smaller than reported in a meta-analysis
on 55 studies (1.1 v. 1.4 to 1.7) (Dudley et al., 2016).
Nonetheless, future research is warranted to explore more specific
cognitive mediation, such as working memory and executive
functions (Falcone et al., 2015; Garety et al., 2013; González
et al., 2018), between JTC and psychosis using more trials of
the Beads Task. The inclusion of more trials in future studies
would permit a more detailed interrogation of the task
(Ermakova et al., 2014, 2018). For example, the use of multiple
trials allows modelling of latent variables such as the probing of
the distinct roles of cognitive noise and alterations in the per-
ceived ‘cost’ of information sampling, which may have partially
distinct genetic bases. We did not measure delusions with a symp-
tom severity rating scale, but rather calculated a measure of a
delusions factor using an item-response analysis from OPCRIT
identified symptoms, so we caution over-interpretation of the
analysis of the relation between DTD and delusions within the
patient group. The CAPE self-report questionnaire was only
Table 2. Linear regressions of PRS predicting DTD
Draws-to-decision (outcome)
B/S.E. p value 95% CI R2 (%) Adj R2 (%)
Case v. Controla −0.9/0.3 0.001 −1.4 to −0.4 9 8
SZ PRSa 0.2/0.3 0.64 −0.5 to 0.8 9 7
SZ PRSb 0.5/0.4 0.17 −0.2 to 1.2 9 8
SZ PRSc 0.4/0.3 0.23 −0.3 to 1.1 13 11
IQ PRSa 0.5/0.1 <0.001 0.3–0.8 10 8
IQ PRSb 0.5/0.1 <0.001 0.2–0.7 10 9
IQ PRSc 0.3/0.1 0.017 0.1–0.6 13 11
SZ, schizophrenia; PRS, polygenic risk score; IQ, intelligent quotient.
aAdjusted for age, sex and 20 principal components for population stratification.
bAdjusted for case/control, age, sex and 20 principal components for population stratification.
cAdjusted for case/control, age, sex, IQ and 20 principal components for population stratification.
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completed by controls, in accordance with its original design for
use in community samples.
Implications
Our results suggested that the tendency to jump to conclusions
may be associated with psychosis liability via a general cognitive
pathway. In fact, improvements on data-gathering resulting in
delayed decision making seem to be driven by cognitive mechan-
isms as shown in Randomised Control Trials comparing
Metacognitive Training (MCT) – which JTC is a core module –
with Cognitive Remediation Therapy in schizophrenia spectrum
disorders (Moritz et al., 2013, 2014). However, psychosis liability
does not necessarily translate to other outcomes of interest in
psychosis, such as prognosis; for example, Andreou (Andreou
et al., 2014) using the same sample as Moritz (Moritz et al.,
2013) found that JTC was the only significant predictor of
improvement in vocational status at 6 months follow up in
terms of probability of regaining full employment status.
Similarly, Dudley (Dudley et al., 2013) found that patients who
displayed stable JTC after 2 years showed an increase in symptom-
atology, whereas stable non-jumpers showed a reduction, as did
those who switched to be a non-jumper. Although the aforemen-
tioned study did not account for cognition, results are in line
with the literature showing the efficacy of MCT on delusion
severity and general functioning up to 3-year-follow-up
(Favrod et al., 2014; Moritz et al., 2013, 2014), and even in indi-
viduals with recent onset of psychosis (Ochoa et al., 2017).
Moreover, a recent study (Rodriguez et al., 2018) which fol-
lowed up the FEP sample reported in Falcone et al., (2015),
showed that JTC at baseline predicted poorer outcome in
terms of more days of hospitalisation, compulsory admissions
and higher risk of police intervention at 4-year follow-up,
even after controlling for IQ.
Thus, although JTC bias might be secondary to a cognitive
impairment in the early stages of psychosis, JTC could play an
important role in both delusions’maintenance and clinical outcome.
Therefore, targeting this bias along with other cognitive deficits in
psychosis therapies and interventions might represent a useful strat-
egy to improve outcomes (Andreou et al., 2014; Moritz et al., 2013).
However, our data suggest that specific interventions to address this
particular cognitive bias in terms of psychosis liability may not pro-
vide any advantage over and above cognitive remediation of general
cognitive deficits (Wykes et al., 2007).
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